Pilar Eroles (Ion Cristóbal)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 26

Top Topics

Estrogen Receptor

Positive Breast Cancer

Histone Deacetylase

Top Venues

International journal of molecular sciences

Cell death discovery

Molecular cancer research : MCR

This page only lists publications with an associated author ORCID identifier.

Publications

Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernando, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Marta Tapia, Juan Antonio Carbonell-Asins, Carlos Javier Peña, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer. Cell death discovery 10 (1) (2024)
Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernando, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Marta Tapia, Juan Antonio Carbonell-Asins, Carlos Javier Peña, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer. Cell death discovery 10 (1) (2024)
Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernando, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Marta Tapia, Juan Antonio Carbonell-Asins, Carlos Javier Peña, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer. Cell death discovery 10 (1) (2024)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Marta Tapia, Cristina Hernando, María Teresa Martínez Martínez, Octavio Burgués, Cristina Tebar-Sánchez, Ana Lameirinhas, Anna Ágreda-Roca, Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lluch, Begoña Bermejo, Pilar Eroles
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies. Cancers 15 (18) (2023)
Marta Sanz-Álvarez, Melani Luque, Miriam Morales-Gallego, Ion Cristóbal, Natalia Ramírez-Merino, Yamileth Rangel, Yann Izarzugaza, Pilar Eroles, Joan Albanell, Juan Madoz-Gúrpide, Federico Rojo
Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. International journal of molecular sciences 25 (1) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Paula Cabello, Sandra Torres-Ruiz, Anna Adam-Artigues, Jaume Forés-Martos, María Teresa Martínez, Cristina Hernando, Sandra Zazo, Juan Madoz-Gúrpide, Ana Rovira, Octavio Burgués, Federico Rojo, Joan Albanell, Ana Lluch, Begoña Bermejo, Juan Miguel Cejalvo, Pilar Eroles
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer. Cancers 15 (7) (2023)
Marta Sanz-Álvarez, Melani Luque, Miriam Morales-Gallego, Ion Cristóbal, Natalia Ramírez-Merino, Yamileth Rangel, Yann Izarzugaza, Pilar Eroles, Joan Albanell, Juan Madoz-Gúrpide, Federico Rojo
Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. International journal of molecular sciences 25 (1) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Marta Sanz-Álvarez, Melani Luque, Miriam Morales-Gallego, Ion Cristóbal, Natalia Ramírez-Merino, Yamileth Rangel, Yann Izarzugaza, Pilar Eroles, Joan Albanell, Juan Madoz-Gúrpide, Federico Rojo
Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. International journal of molecular sciences 25 (1) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
David Casadevall, Anna Hernández-Prat, Sara García-Alonso, Oriol Arpí-Llucià, Silvia Menéndez, Mengjuan Qin, Cristina Guardia, Beatriz Morancho, Francisco Javier Sánchez-Martín, Sandra Zazo, Elena Gavilán, Mohammad A Sabbaghi, Pilar Eroles, Juan Miguel Cejalvo, Ana Lluch, Federico Rojo, Atanasio Pandiella, Ana Rovira, Joan Albanell
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer. Molecular cancer research : MCR 20 (7) (2022)
Birlipta Pattanayak, Ana Lameirinhas, Sandra Torres-Ruiz, Octavio Burgués, Ana Rovira, María Teresa Martínez Martínez, Marta Tapia, Sandra Zazo, Joan Albanell, Federico Rojo, Begoña Bermejo, Pilar Eroles
Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway. International journal of molecular sciences 23 (21) (2022)
Melani Luque, Ion Cristóbal, Marta Sanz-Álvarez, Andrea Santos, Sandra Zazo, Pilar Eroles, Oriol Arpí, Ana Rovira, Joan Albanell, Juan Madoz-Gúrpide, Jesús García-Foncillas, Federico Rojo
CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer. Journal of clinical medicine 11 (6) (2022)
Anna Adam-Artigues, Enrique J Arenas Lahuerta, Alex Martínez-Sabadell, Fara Brasó-Maristany, Raimundo Cervera, Eduardo Tormo, Cristina Hernando, María Teresa Martínez Martínez, Juan Antonio Carbonell-Asins, Soraya Simón, Jesús Poveda, Santiago Moragón, Sandra Zazo, Débora Martínez, Ana Rovira, Octavio Burgués, Federico Rojo, Joan Albanell, Begoña Bermejo, Ana Lluch, Aleix Prat, Joaquín Arribas, Pilar Eroles, Juan Miguel Cejalvo
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Science advances 8 (20) (2022)
Melani Luque, Marta Sanz-Álvarez, Andrea Santamaría, Sandra Zazo, Ion Cristóbal, Lorena de la Fuente, Pablo Mínguez, Pilar Eroles, Ana Rovira, Joan Albanell, Juan Madoz-Gúrpide, Federico Rojo
Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer. International journal of molecular sciences 22 (24) (2021)
Iris Garrido-Cano, Birlipta Pattanayak, Anna Adam-Artigues, Ana Lameirinhas, Sandra Torres-Ruiz, Eduardo Tormo, Raimundo Cervera, Pilar Eroles
MicroRNAs as a clue to overcome breast cancer treatment resistance. Cancer metastasis reviews (2021)
Cristina Guardia, Giampaolo Bianchini, Oriol Arpí-LLucià, Silvia Menendez, David Casadevall, Barbara Galbardi, Matteo Dugo, Sonia Servitja, Juan Carlos Montero, Luis Soria-Jiménez, MohammadA Sabbaghi, Raul Peña, Juan Madoz-Gúrpide, Belen Lloveras, Ana Lluch, Pilar Eroles, Joaquin Arribas, Atanasio Pandiella, Luca Gianni, Federico Rojo, Ana Rovira, Joan Albanell
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (18) (2021)
Cristina Hernando, Belén Ortega-Morillo, Marta Tapia, Santiago Moragón, María Teresa Martínez, Pilar Eroles, Iris Garrido-Cano, Anna Adam-Artigues, Ana Lluch, Begoña Bermejo, Juan Miguel Cejalvo
Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. International journal of molecular sciences 22 (15) (2021)
Anna Adam-Artigues, Iris Garrido-Cano, Juan Antonio Carbonell-Asins, Ana Lameirinhas, Soraya Simón, Belén Ortega-Morillo, María Teresa Martínez, Cristina Hernando, Vera Constâncio, Octavio Burgues, Begoña Bermejo, Rui M Henrique, Ana Lluch, Carmen Jerónimo, Pilar Eroles, Juan Miguel Cejalvo
Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer. Cancers 13 (11) (2021)
Sandra Zazo, Paula González-Alonso, Ester Martín-Aparicio, Cristina Chamizo, Melani Luque, Marta Sanz-Álvarez, Pablo Mínguez, Gonzalo Gómez-López, Pilar Eroles, Cristina Caramés, Jesús García-Foncillas, Ana Lluch, Oriol Arpí, Ana Rovira, Joan Albanell, Juan Madoz-Gúrpide, Federico Rojo
Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer. Molecular cancer therapeutics 19 (8) (2020)
Jorge Gómez-Miragaya, Sebastián Morán, Maria Eréndira Calleja-Cervantes, Alejandro Collado-Sole, Laia Paré, Antonio Gómez, Violeta Serra, Lacey E Dobrolecki, Michael T Lewis, Angel Diaz-Lagares, Pilar Eroles, Aleix Prat, Manel Esteller, Eva González-Suárez
The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. Molecular cancer research : MCR 17 (10) (2019)
Aura Muntasell, Sònia Servitja, Mariona Cabo, Begoña Bermejo, Sandra Pérez-Buira, Federico Rojo, Marcel Costa-García, Oriol Arpí, Manuela Moraru, Laia Serrano, Ignasi Tusquets, María Teresa Martínez Martínez, Gemma Heredia, Andrea Vera, María Martínez-García, Laura Soria, Laura Comerma, Sara Santana-Hernández, Pilar Eroles, Ana Rovira, Carlos Vilches, Ana Lluch, Joan Albanell, Miguel López-Botet
High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer. Cancer immunology research 7 (8) (2019)